Peptidomics for cancer diagnosis: present and future.
Analysis of peptides in biological fluids by mass spectrometry holds promise of providing diagnostic and prognostic information for cancer and other diseases. Before this technology is used clinically, it is important to understand its advantages and limitations. These are summarized, along with proposals, on how to proceed in the future.
Diamandis
Eleftherios P
EP
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. ediamandis@mtsinai.on.ca
D001826:Body Fluids / Q000737:chemistry*; D019295:Computational Biology / Q000379:methods; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis*; D010455:Peptides / Q000032:analysis* / Q000302:isolation & purification; D040901:Proteomics / Q000379:methods* / Q000639:trends; D020539:Sequence Analysis, Protein / Q000379:methods
D010455:Peptides